These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 26683758)

  • 1. Re: Grace L. Lu-Yao, Peter C. Albertsen, Dirk F. Moore, Yong Lin, Robert S. DiPaola, Siu-Long Yao. Fifteen-year Outcomes Following Conservative Management Among Men aged 65 Years or Older with Localized Prostate Cancer. Eur Urol 2015;68:805-11.
    Froehner M; Koch R; Wirth MP
    Eur Urol; 2016 Jun; 69(6):e130. PubMed ID: 26683758
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Michael Froehner, Rainer Koch, Manfred P. Wirth's Letter to the Editor re: Grace L. Lu-Yao, Peter C. Albertsen, Dirk F. Moore, Yong Lin, Robert S. DiPaola, Siu-Long Yao. Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer. Eur Urol 2015;68:805-11.
    Albertsen PC; Lu-Yao GL
    Eur Urol; 2016 Jun; 69(6):e131-2. PubMed ID: 26706104
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Sung Kim, Shunhua Shen, Dirk F. Moore, et al. Late gastrointestinal toxicities following radiation therapy for prostate cancer. Eur Urol 2011;60:908-16.
    Rossi CJ
    Eur Urol; 2012 May; 61(5):e43; author reply e44. PubMed ID: 22326675
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Phillip J. Gray, Chun Chieh Lin, Matthew R. Cooperberg, Ahmedin Jemal, Jason A. Efstathiou. Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer. Eur Urol 2017;71:729-37.
    Gild P; von Landenberg N; Cole AP
    Eur Urol; 2017 Jun; 71(6):e181-e182. PubMed ID: 28040352
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Jeffrey C. Weinreb, Jelle O. Barentsz, Peter L. Choyke, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 2016;69:16-40: Is Contrast-enhanced Magnetic Resonance Imaging Really Necessary When Searching for Prostate Cancer?
    Rud E; Baco E
    Eur Urol; 2016 Nov; 70(5):e136. PubMed ID: 27126376
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Peter K.-F. Chiu, Chi-Fai Ng, Axel Semjonow, et al. A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings. Eur Urol 2019;75:558-61.
    Heidegger I; Pichler R
    Eur Urol; 2019 Jun; 75(6):e158-e159. PubMed ID: 30616947
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-9 and re: John Anderson. Androgen-deprivation therapy--It's all a matter of timing. Eur Urol 2008;53:869-71.
    Kirollos MM
    Eur Urol; 2009 Feb; 55(2):e40-2; author reply e45-6. PubMed ID: 18760526
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Survival after Conservative Management versus External Beam Radiation Therapy in Elderly Patients with Localized Prostate Cancer.
    Griebling TL
    J Urol; 2017 Jan; 197(1):157-158. PubMed ID: 27979516
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Johan Lindberg, Anna Kristiansen, Peter Wiklund, Henrik Grönberg, Lars Egevad. Tracking the Origin of Metastatic Prostate Cancer. Eur Urol 2015;67:819-22.
    Piva F; Santoni M; Scarpelli M; Briganti A; Montorsi F; Montironi R
    Eur Urol; 2015 Dec; 68(6):e134-5. PubMed ID: 26215609
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Neil E. Martin, Laura Massey, Caleb Stowell, et al. Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. Eur Urol 2015;67:460-7.
    Wittmann D; Skolarus TA
    Eur Urol; 2016 Jun; 69(6):e125-6. PubMed ID: 26873838
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply from Authors re: Adri C. Voogd, Rob H.A. Verhoeven. Treatment of the Primary Tumour in the Presence of Metastases: Lessons from Breast Cancer. Eur Urol 2016;69:797-9Reply from Authors re: Alfred I. Neugut, Edward P. Gelmann. Treatment of the Prostate in the Presence of Metastases: Lessons from Other Solid Tumors. Eur Urol 2016;69:795-6: The Time Is Ripe to Test the Hypothesis that Radical Prostatectomy Improves Survival in Men with Distant Metastatic Prostate Cancer.
    Sooriakumaran P; Graefen M; Wiklund P
    Eur Urol; 2016 May; 69(5):800-1. PubMed ID: 26306698
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: William C. Jackson, Matthew J. Schipper, Skyler B. Johnson, et al. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol 2016;69:50-7. Re: Ronald C. Chen. Postprostatectomy Radiotherapy: Whether and How Long to Give Concurrent Androgen Deprivation Therapy. Eur Urol 2016;69:58-9: Which patients need treatment intensification?
    Dal Pra A; Spahn M
    Eur Urol; 2016 Apr; 69(4):e74-e75. PubMed ID: 26508311
    [No Abstract]   [Full Text] [Related]  

  • 13. Costs of conservative management of early-stage prostate cancer compared to radical prostatectomy-a claims data analysis.
    Brandes A; Koerber F; Schwarzkopf L; Hunger M; Rogowski WH; Waidelich R
    BMC Health Serv Res; 2016 Nov; 16(1):664. PubMed ID: 27863486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reply to Daniela Wittmann, Ted A. Skolarus' Letter to the Editor re: Neil E. Martin, Laura Massey, Caleb Stowell, et al. Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. Eur Urol 2014;67:460-7.
    Martin NE; Stowell C
    Eur Urol; 2016 Jun; 69(6):e127. PubMed ID: 26873843
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Marco Borghesi, Hashim Ahmed, Robert Nam, et al. Complications After Systematic, Random, and Image-guided Prostate Biopsy. Eur Urol 2017;71:353-65.
    Grummet J; Pepdjonovic L; Moon D
    Eur Urol; 2017 May; 71(5):e143-e144. PubMed ID: 28029398
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Lu Yang, Shi Qiu and Qiang Wei's Letter to the Editor re: Christopher E. Bayne, Stephen B. Williams, Matthew R. Cooperberg, et al. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. Eur Urol 2016;69:775-87.
    Bayne CE; Williams -B; Chapin BF
    Eur Urol; 2017 Feb; 71(2):e51. PubMed ID: 27461403
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.04.039.
    Stephan C; Cammann H; Jung K
    Eur Urol; 2015 Nov; 68(5):e106-7. PubMed ID: 26215600
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Stephen H. Culp, Paul F. Schellhammer, Michael B. Williams. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 2014;65:1058-66.
    Bayne CE
    Eur Urol; 2014 Jun; 65(6):e99. PubMed ID: 24411281
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Stephen H. Culp, Paul F. Schellhammer, Michael B. Williams. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 2014;65:1058-66.
    Ost P; Briganti A; Giannarini G;
    Eur Urol; 2014 Jun; 65(6):e97-8. PubMed ID: 24365126
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Urs E. Studer, Laurence Collette, Peter Whelan, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008;53:941-9.
    Ragavan N; Singh PB; Martin FL; Baird AD
    Eur Urol; 2009 Feb; 55(2):e43-4. PubMed ID: 18771846
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.